Explore HGH dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
Recombinant human growth hormone (rhGH, somatropin) is a 191-amino-acid protein produced by recombinant DNA technology, identical in sequence to pituitary-derived human GH. It is FDA-approved under several brand names (Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Zomacton) for a defined set of paediatric and adult indications — most importantly paediatric GH deficiency, Turner syndrome, chronic renal insufficiency in children, adult GH deficiency, and HIV-associated wasting.[1] Outside of these specifically labelled indications, distribution of rhGH for anti-aging, body-composition, or athletic-performance purposes is explicitly prohibited under U.S. federal law (21 U.S.C. § 333(f)(4)(B)).[2]
rhGH binds the GH receptor (GHR), a class I cytokine receptor, on hepatocytes, chondrocytes, adipocytes, and other tissues. Dimerised GHR activates JAK2/STAT5 signalling, driving hepatic production of IGF-1 (the dominant mediator of long-bone growth and protein anabolism) and direct effects on adipose lipolysis, insulin antagonism, and sodium retention.[3]
FDA-approved indications include paediatric GH deficiency, Turner syndrome, Prader-Willi syndrome (with specific safety contraindications), small-for-gestational-age children, chronic renal insufficiency in children, idiopathic short stature, SHOX deficiency, Noonan syndrome, adult GH deficiency, and HIV-associated wasting/cachexia.[1] Off-label use for anti-aging, body composition, or athletic performance is specifically prohibited by 21 U.S.C. § 333(f) and carries criminal penalties for distributors.[2] **Typical dose:** FDA-approved doses are indication-specific and weight-based. Adult GH deficiency: 0.2–0.4 mg/day subcutaneous, titrated by serum IGF-1 to keep it within the age-and-sex-specific normal range. Paediatric GH deficiency: 0.16–0.24 mg/kg/week divided into 6–7 daily doses. The off-label "anti-aging" doses commonly seen in non-medical use (often 2–4 IU/day or higher) substantially exceed approved adult dose ranges and have not been characterised in long-term outcome studies.
FDA-approved (multiple brands) for defined paediatric and adult indications. Distribution for anti-aging, body-composition, or athletic-performance use is explicitly prohibited under 21 U.S.C. § 333(f).
HGH has a reported half-life of ~2–3 hours (subcutaneous). The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. Subcutaneous somatropin clears within hours, so daily dosing produces a once-a-day pulse rather than a steady plasma level; the downstream IGF-1 response lasts longer than the GH itself. Pharmacokinetic source: FDA label (somatropin, e.g. Genotropin). It is catalogued under Other Peptides on WPA.
25 HGH reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.